Latest & greatest articles for alzheimer's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alzheimer's disease

1. A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease

studies pointed out that a “bidirectional relationship” exists between the two diseases and must be considered. Patients with AD typically do not possess the cognitive or physical ability to perform proper oral hygiene, therefore predisposing them to periodontal disease. Applicability Due to the increasing life expectancy of our patients and chronic nature of both periodontal and Alzheimer’s disease, dental providers will be confronted with both conditions. Therefore, it is imperative that we (...) A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease UTCAT3403, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease Clinical Question Is a patient with periodontal disease at higher risk of developing Alzheimer’s disease, compared to an individual without periodontal disease? Clinical Bottom Line

2019 UTHSCSA Dental School CAT Library

2. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. Full Text available with Trip Pro

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources

2019 Cochrane

3. ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors Jill S. Goldman, MS, MPhil 1,2 , Susan E. Hahn, MS 3 , Jennifer Williamson Catania, MS, MPH 1,2 , Susan LaRusse-Eckert, MS 2 , Melissa (...) the following considerations in reaffirming this document: 1. To use the phrase “pathogenic variant” rather than the word “mutation” in discussing pathogenic variants related to autosomal dominant early-onset Alzheimer disease. This would be consistent with current ACMG/AMP Guidelines for Variant Interpretation and Reporting 1 . 2. Because this document no longer meets the criteria for an evidence-based practice guideline by either the American College of Medical Genetics and Genomics (ACMG) or National

2019 American College of Medical Genetics and Genomics

4. Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial (Abstract)

Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial Our study aimed to assess the effect of a 12-month vitamin D supplementation on cognitive function and amyloid beta (Aβ)-related biomarkers in subjects with Alzheimer's disease (AD). METHODS : This was a randomised, double-blind, placebo-controlled trial. 210 AD patients were randomly divided

2019 EvidenceUpdates

5. Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow

Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Prescrire IN ENGLISH - Spotlight ''Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow'', 1 May 2019 {1} {1} {1} | | > > > Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow A study conducted by the independent French medical journal Prescrire shows a reduction of only around 26% in the number of patients in France exposed to at least one Alzheimer's disease drug between 2012 and 2017. In approximately 3 out of 4 newly exposed patients, treatment lasted for more than 6 months, despite the proven harms. In France, as far back as 2011, the pharmacoeconomic committee

2019 Prescrire

6. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease Full Text available with Trip Pro

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened (...) carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score

2019 EvidenceUpdates

7. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Full Text available with Trip Pro

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due (...) to Alzheimer's disease.We conducted a randomized, double-blind, placebo-controlled, 104-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia. The primary outcome was the change from baseline to week 104 in the score on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores

2019 NEJM Controlled trial quality: predicted high

8. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. Full Text available with Trip Pro

, and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60 (...) Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.Nationwide case-control study.Finnish national population and drug register, between 1999 and 2013.All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician

2019 BMJ

9. Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. Heterogeneity of outcomes in Alzheimer's disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE) ε4 genotype, family history of AD, and amyloid abnormalities.Modeling estimated the number of randomized patients needed to detect a 2-point

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

10. Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Full Text available with Trip Pro

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. Preliminary studies have shown that treatment with plasma exchange (PE) plus therapeutic albumin replacement in patients with Alzheimer's disease (AD) induced mobilization of plasma and cerebrospinal fluid amyloid β protein, associated with an improvement in memory and language functions, as well as the stabilization of brain perfusion, which persisted after treatment

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

11. Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease. Full Text available with Trip Pro

Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease. Animal models of Alzheimer's disease show that exercise may modify β-amyloid (Aβ) deposition. We examined the effect of a 16-week exercise intervention on cortical Aβ in patients with mild-to-moderate Alzheimer's disease.Thirty-six patients with Alzheimer's disease were randomized to either one hour of aerobic exercise three times weekly for 16 weeks or usual care. Pre and post intervention

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

12. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Full Text available with Trip Pro

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive impairment. This long preclinical period provides an opportunity for clinical trials designed to prevent or delay the onset of cognitive impairment due to AD. Under (...) the umbrella of the Alzheimer's Prevention Initiative Generation Program, therapies targeting Aβ, including CNP520 (umibecestat), a β-site-amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor, and CAD106, an active Aβ immunotherapy, are in clinical development in preclinical AD.The Alzheimer's Prevention Initiative Generation Program comprises two pivotal (phase 2/3) studies that assess the efficacy and safety of umibecestat and CAD106 in cognitively unimpaired individuals with high risk

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

13. Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. Full Text available with Trip Pro

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease. Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy as measured by volumetric magnetic resonance imaging (MRI).In the EXPEDITION3 phase 3 trial (...) , participants with mild Alzheimer's disease were randomized to receive intravenous infusions of either 400 mg of solanezumab or placebo every 4 weeks for 76 weeks. Volumetric MRI scans were acquired at baseline and at 80 weeks from 275 MRI facilities using a standardized imaging protocol. A subset of 1462 patients who completed both MRI and 14-item Alzheimer's Disease Assessment Scale-Cognitive Subscale assessments at both time points were selected for analysis. Longitudinal MRI volume changes were analyzed

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

14. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. Full Text available with Trip Pro

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. S47445 is a novel positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors that may emerge as a favorable candidate for the symptomatic treatment of cognitive and depressive disorders in patients suffering from Alzheimer's disease (AD) of mild to moderate severity (...) and with depressive symptoms.For this double-blind, placebo-controlled 24-week phase II trial, 520 outpatients aged between 55 and 85 years, with probable AD at mild to moderate stages (a Mini-Mental State Examination score of 24-15 inclusive) and exhibiting depressive symptoms (Cornell Scale for Depression in Dementia [CSDD] ≥ 8) were recruited in twelve countries and randomized to 3 doses of S47445 (5-15-50 mg) or placebo. The primary end point was the change from baseline in the 11-item Alzheimer's Disease

2019 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: predicted high

15. Treatment of epilepsy for people with Alzheimer's disease. Full Text available with Trip Pro

Treatment of epilepsy for people with Alzheimer's disease. Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of these treatments; this review aims to review those different modalities. This is an updated version

2018 Cochrane

16. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial Full Text available with Trip Pro

(258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo (...) . The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific

2018 EvidenceUpdates Controlled trial quality: predicted high

17. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Discover Portal Discover Portal Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Published on 11 December 2015 doi: This follow up study (...) examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil. However, there was no difference over

2018 NIHR Dissemination Centre

18. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. Full Text available with Trip Pro

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. The positron emission tomography (PET) tracer [18F]flortaucipir allows in vivo quantification of paired helical filament tau, a core neuropathological feature of Alzheimer disease (AD), but its diagnostic utility is unclear.To examine the discriminative accuracy of [18F]flortaucipir for AD vs non-AD neurodegenerative disorders.In this cross-sectional study, 719 (...) neurodegenerative disorders. The AUCs for all 5 [18F]flortaucipir ROIs were higher (AUC range, 0.92-0.95) compared with the 3 volumetric MRI measures (AUC range, 0.63-0.75; all ROIs P < .001). Diagnostic performance of the 5 [18F]flortaucipir ROIs were lower in MCI due to AD (AUC range, 0.75-0.84).Among patients with established diagnoses at a memory disorder clinic, [18F]flortaucipir PET was able to discriminate AD from other neurodegenerative diseases. The accuracy and potential utility of this test

2018 JAMA

19. Alzheimer?s disease

, pharmacology, genetic medicine, nursing, health economics, health services research, and family caregiving, and a public representative. In addition, 20 experts from pertinent fields 2010 2. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: Dementia is a progressive global cognitive impairment syndrome . In 2010, more than 35 million people worldwide were estimated to be living with dementia. Some (...) ,” in response to legislation signed by President Obama in January, 2011 establishing the National Alzheimer’s Project Act. The overarching goal of the Plan is to “prevent (...) or effectively treat Alzheimer’s Disease by 2025.” We now have an estimated 5.5 million people who are living with this illness [1] and these numbers are only expected to grow with the aging [2]. The U.S. Preventive Services Task Force finds no evidence to recommend widespread dementia screening[3], however the Affordable Care Act

2018 Trip Latest and Greatest

20. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis (Abstract)

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis This study (registered with PROSPERO, CRD42018085967) compares the efficacy (i.e. pro-cognitive effects) and acceptability of antidiabetic agents for Alzheimer's disease (AD) and mild cognitive impairment (MCI). Cochrane Library (CENTRAL), PubMed/MEDLINE, EMBASE and PsycINFO were searched from inception to January 15, 2018

2018 EvidenceUpdates